<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition</h1>
  <ul>
<li>Novartis will pay $48.00 per share in cash at closing, a 59% premium to Tourmaline’s September 8 closing price and 127% above its 60-day volume-weighted average.</li>
<li>The deal is expected to close in the fourth quarter of 2025.</li>
<li>If the milestone is achieved, total consideration, including the CVR, would be approximately $1.7 billion.</li>
<li>In April, Novartis acquired Regulus Therapeutics for an initial payment of $7.00 per share in cash or $0.8 billion.</li>
<li>Other Deals In 2025 To Bolster Heart and Kidney Drug Portfolio Earlier in 2025, Novartis agreed to acquire Anthos Therapeutics Inc.</li>
<li>for an upfront payment of $925 million and potential additional payments of up to $2.15 billion upon achieving specified regulatory and sales milestones.</li>
<li>(NASDAQ:TRML) shares surged Tuesday after Novartis AG (NYSE:NVS) announced a $1.4 billion acquisition of the U.S.-based biotech, strengthening the Swiss drugmaker’s pipeline of cardiovascular and kidney treatments.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/novartis-expand-heart-drug-portfolio-121032541.html">Source</a> · 2025-09-09T12:10:32+00:00</p>
</body>
</html>